China’s Healthcare System and Reform

This volume provides a comprehensive review of China’s healthcare system and policy reforms in the context of the global economy. Following a value-chain framework, the 16 chapters cover the payers, the providers, and the producers (manufacturers) in China’s system. It also provides a detailed analysis of the historical development of China’s healthcare system, the current state of its broad reforms, and the uneasy balance between China’s market-driven approach and governmental regulation. Most importantly, it devotes considerable attention to the major problems confronting China, including chronic illness, public health, and long-term care and economic security for the elderly. Burns and Liu have assembled the latest research from leading health economists and political scientists, as well as senior public health officials and corporate executives, making this book an essential read for industry professionals, policy-makers, researchers, and students studying comparative health systems across the world.


Gordon G. Liu is a PKU Yangtze River Scholar Professor of Economics at Peking University National School of Development and Director of PKU China Center for Health Economic Research (CCHER). He sits on China’s State Council Health Reform Expert
Advisory Committee and the UN Leadership Council of Sustainable Development Solution Network (SDSN). He was the president of Chinese Economists Society (CES) for 2004–2005. He has served as associate editor for academic journals including *Health Economics, China Economic Quarterly, and Value in Health.*
China’s Healthcare System and Reform

Edited by

LAWTON ROBERT BURNS
The Wharton School, University of Pennsylvania

GORDON G. LIU
Peking University National School of Development, Beijing
# Contents

List of Figures vii  
List of Tables xi  
List of Contributors xiii  
Foreword xix  
*by William C. Hsiao, PhD*  
Preface xxii  
Acknowledgments xxiii  

## PART I  INTRODUCTION: ANALYTIC FRAMEWORK, HISTORY, AND PUBLIC HEALTH

1. China’s Healthcare Industry: A System Perspective  
   *Lawton Robert Burns and Gordon G. Liu*  

2. History of China’s Healthcare System  
   *Lawton Robert Burns and Yanzhong Huang*  

3. China’s Public Health System and Infrastructure  
   *Xiaofeng Liang and Lawton Robert Burns*  

## PART II  HEALTHCARE REFORM

4. Epidemiological Transition and Health System Reforms in China  
   *Gordon G. Liu and Sam Krumholz*  

5. China’s Healthcare Reform: Status and Outlook  
   *Claudia Süssmuth-Dyckerhoff and Florian Then*  

6. The Challenge of Non-communicable Diseases (NCDs) in China: Government Responses and Opportunities for Reform  
   *Tsung-Mei Cheng*
### Contents

**PART III HEALTHCARE PROVIDERS**

7 China’s Physician and Nurse Workforce 179  
*Lawton Robert Burns*

8 China’s Hospital Sector 219  
*Gerard M. La Forgia and Winnie Yip*

9 United Family Healthcare (Chindex International): A Case Study 250  
*Vanessa Folkerts and Roberta Lipson*

10 Providing and Financing Elder Care in China 269  
*John Whitman and Lawton Robert Burns*

**PART IV INSURERS AND REIMBURSEMENT**

11 Health Insurance in China 291  
*Ambar La Forgia and Lawton Robert Burns*

12 Health Insurance and Chronic Disease Control: Quasi-experimental Evidence from Hypertension in Rural China 321  
*Karen Eggleston, M. Kate Bundorf, Margaret Triyana, Yan Wang, and Sen Zhou*

13 Drug Pricing and Health Technology Assessment in China and Other Asian Markets 335  
*Gordon G. Liu, Nan Luo, and Zhongyun Zhao*

**PART V PRODUCT MANUFACTURERS**

14 China’s Pharmaceutical Sector 351  
*Rachel Lee and Lawton Robert Burns*

15 China’s Medical Technology Sector 383  
*James Deng and Lawton Robert Burns*

16 Life Sciences Investment and Biotechnology in China 428  
*Stephen M. Sammut and Lawton Robert Burns*

Index 451
Figures

1.1 The iron triangle of healthcare: balancing act 4
1.2 Per capita national health expenditures in China 4
1.3 The Millennium Preston curve 11
1.4 Issues behind cost–quality relationship 12
1.5 Healthcare financing structures in China and India in 2013 13
1.6 Age distributions in China and India 14
1.7 “Control knobs” framework 16
1.8 The healthcare value chain 18
1.9 Overview of China’s healthcare system 18
1.10 The healthcare quadrilemma 19
1.11 Dynamic model of transitions 20
1.12 Health and healthcare 21
1.13 Population with access to improved sanitation facilities, 1990–2012 21
1.14 Population with access to improved water sources, 1990–2012 22
1.15 Change in alcohol consumption per capita, 2000–2010 22
1.16 Percentage change in public health spending, 2002–2012 23
1.17 Infant mortality rate, 1990–2012 23
1.18 Life expectancy at birth, 1990–2012 24
1.19 Human Development Index, 2012, and change from 1992 to 2012 24
1.20 Empirical relationships between transitions 25
1.21 Annual per capita growth of GDP and total health expenditures (THE) 26
2.1 China’s healthcare structure 42
2.2 Expansion of insurance coverage, 2005–2011 58
2.3 Complex map of government stakeholders 62
3.1 Disparity and diversity in life expectancy and per capita GDP across China’s provinces, 2010 76
3.2 Decline in maternal mortality rate (MMR): urban versus rural areas 77
3.3 List of notifiable diseases 78
3.4 The incidence rate of infectious diseases (categories A and B) 78
3.5 The mortality rate of infectious diseases (categories A and B) 79
3.6 Elimination of measles 79
3.7 Number of infectious disease cases by transmission routes in China, 1990–2013 80
3.8 Annual reported HIV-positive and AIDS cases by transmission source, 1985–2013 83
3.9 Breakdown of newly reported HIV cases, 1985–2013 83
3.10 Problems and challenges of tuberculosis control 87
3.11 Prevalence of NCD risk factors in adults aged >18 in 2010 90
3.12 Prevalence and patient numbers for different NCDs 90
3.14 Economic burden of NCDs: comparison of average hospital cost and household income, 2012 93
3.15 Cigarette production in China, 1952–2013 95
3.16 Public health infrastructure in China 103
3.17 China CDC’s organizational structure, 2011 104
3.18 National Center for Non-communicable Diseases Control organizational structure 105
### List of Figures

<table>
<thead>
<tr>
<th>Figure</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.19</td>
<td>China CDC core functions</td>
<td>105</td>
</tr>
<tr>
<td>3.20</td>
<td>China CDC funding, 2001–2010</td>
<td>106</td>
</tr>
<tr>
<td>3.21</td>
<td>Working principle of the web-based reporting system</td>
<td>107</td>
</tr>
<tr>
<td>3.22</td>
<td>The information system for NCDs in China</td>
<td>108</td>
</tr>
<tr>
<td>3.23</td>
<td>NCD strategy</td>
<td>109</td>
</tr>
<tr>
<td>3.24</td>
<td>Key tasks for improving public health systems</td>
<td>111</td>
</tr>
<tr>
<td>3.25</td>
<td>Framework for healthcare system reform</td>
<td>111</td>
</tr>
<tr>
<td>4.1</td>
<td>Change in number of deaths of five major chronic diseases, 1990 and 2010</td>
<td>120</td>
</tr>
<tr>
<td>4.2</td>
<td>Change in age-standardized mortality rates of five major chronic diseases, 1990 and 2010</td>
<td>121</td>
</tr>
<tr>
<td>4.3</td>
<td>Total number of community and township health centers, 2002–2011</td>
<td>127</td>
</tr>
<tr>
<td>4.4</td>
<td>Beds per 1,000 population in urban and rural China</td>
<td>129</td>
</tr>
<tr>
<td>5.1</td>
<td>Progress on the five key priorities</td>
<td>138</td>
</tr>
<tr>
<td>5.2</td>
<td>Reimbursement rates vary even at the same location</td>
<td>140</td>
</tr>
<tr>
<td>5.3</td>
<td>Medical facilities’ inpatient flow, in million patients</td>
<td>144</td>
</tr>
<tr>
<td>5.4</td>
<td>Early success with DRGs in Beijing Class III hospital pilots</td>
<td>147</td>
</tr>
<tr>
<td>6.1</td>
<td>Health spending on NCDs in China, by type of service, 2013</td>
<td>162</td>
</tr>
<tr>
<td>7.1</td>
<td>Rural healthcare infrastructure, 1950–2000</td>
<td>185</td>
</tr>
<tr>
<td>7.2</td>
<td>Physician demography in public and private hospitals</td>
<td>187</td>
</tr>
<tr>
<td>7.3</td>
<td>Number and percentage of doctors by specialties in 2005</td>
<td>188</td>
</tr>
<tr>
<td>7.4</td>
<td>Distribution of healthcare workforce</td>
<td>192</td>
</tr>
<tr>
<td>7.5</td>
<td>Variations in physician supply by province</td>
<td>192</td>
</tr>
<tr>
<td>7.6</td>
<td>Physicians with four-year college level education</td>
<td>194</td>
</tr>
<tr>
<td>7.7</td>
<td>Physician training by healthcare institution</td>
<td>195</td>
</tr>
<tr>
<td>7.8</td>
<td>Physician career ladder</td>
<td>197</td>
</tr>
<tr>
<td>7.9</td>
<td>Resources and revenues by hospital tier</td>
<td>200</td>
</tr>
<tr>
<td>7.10</td>
<td>Occupancy levels by hospital tier</td>
<td>200</td>
</tr>
<tr>
<td>7.11</td>
<td>Distribution of outpatient visits</td>
<td>201</td>
</tr>
<tr>
<td>7.12</td>
<td>Daily patient visits per physician per level</td>
<td>201</td>
</tr>
<tr>
<td>7.13</td>
<td>Growth of patient visits versus physician supply</td>
<td>202</td>
</tr>
<tr>
<td>7.14</td>
<td>Comparison of physician salaries</td>
<td>203</td>
</tr>
<tr>
<td>7.15</td>
<td>Physician salary/GDP per capita</td>
<td>203</td>
</tr>
<tr>
<td>7.16</td>
<td>CAGR of hospital revenue sources, 2008–2011</td>
<td>205</td>
</tr>
<tr>
<td>7.17</td>
<td>Levers to control physician behavior</td>
<td>208</td>
</tr>
<tr>
<td>7.18</td>
<td>“Precautionary measures” taken by physicians</td>
<td>212</td>
</tr>
<tr>
<td>8.1</td>
<td>Growth in hospitals by ownership, 2005–2013</td>
<td>220</td>
</tr>
<tr>
<td>8.2</td>
<td>Growth in beds by ownership (Unit: 10,000), 2005–2013</td>
<td>220</td>
</tr>
<tr>
<td>8.3</td>
<td>Type of hospitals operated by public sector, 2013</td>
<td>221</td>
</tr>
<tr>
<td>8.4</td>
<td>Type of hospitals operated by private sector, 2013</td>
<td>221</td>
</tr>
<tr>
<td>8.5</td>
<td>Growth of hospital admissions by ownership (Unit: 10,000), 2005–2013</td>
<td>223</td>
</tr>
<tr>
<td>8.6</td>
<td>Growth of outpatient visits by ownership (Unit: 10,000), 2005–2013</td>
<td>223</td>
</tr>
<tr>
<td>8.7</td>
<td>Dispersion of power among ministries and public hospitals</td>
<td>225</td>
</tr>
<tr>
<td>8.8</td>
<td>Management practice domains</td>
<td>226</td>
</tr>
<tr>
<td>8.9</td>
<td>Scores by management practice, China 2015</td>
<td>227</td>
</tr>
<tr>
<td>8.10</td>
<td>Organizational, autonomy, and accountability characteristics of selected public hospital governance reform models, 2015</td>
<td>232</td>
</tr>
<tr>
<td>8.11</td>
<td>Categories and indicators used for performance appraisal and bonuses</td>
<td>237</td>
</tr>
<tr>
<td>9.1</td>
<td>United Family Healthcare roadmap</td>
<td>254</td>
</tr>
<tr>
<td>9.2</td>
<td>Three separate lines of management</td>
<td>255</td>
</tr>
<tr>
<td>9.3</td>
<td>Patient nationality mix, by net revenue</td>
<td>258</td>
</tr>
<tr>
<td>9.4</td>
<td>Revenue composition, by payer type, 2014</td>
<td>259</td>
</tr>
<tr>
<td>9.5</td>
<td>UFH revenue composition by service type</td>
<td>260</td>
</tr>
<tr>
<td>10.1</td>
<td>Age structure of China’s population in 1950, 2010, and 2050 (projected)</td>
<td>270</td>
</tr>
<tr>
<td>10.2</td>
<td>Aging of China’s population, 1950–2050</td>
<td>271</td>
</tr>
</tbody>
</table>
List of Figures ix

11.1 Coverage, reimbursement, and fund surplus of UEBMI, URBMI, and NCMS 298
11.2 Government and out-of-pocket spending on health as a percent of total health expenditures in select countries, 2012 299
11.3 Iron triangle impacts of physician reimbursement 302
11.4 Impacts of hospital reimbursement 303
11.5 Private health insurance as percent of total health expenditures of select countries, 2012 304
11.6 Annual private health insurance premium income 305
11.7 Trends in premiums collected, 2008–2013 308
11.8 Insurer value chain 310
14.1 Growing concentration of pharma sector 352
14.2 Domestic players versus MNCs in large hospital market 353
14.3 China’s pharmaceutical market growth 354
14.4 Shares of hospital, retail, and grassroots markets 355
14.5 Sales and growth of end market 356
14.6 Pharmaceutical market customer segments 357
14.7 MNCs versus local players by therapeutic category 358
14.8 Sales of patent/off-patent originators versus generics 360
14.9 Classification of prescription drugs in China 360
14.10 Sector growth: hospital volume 361
14.11 Trend in average drug price 361
14.12 Per capita drug spend 362
14.13 China’s pharmaceutical market by product segment 362
14.14 Market access in China 363
14.15 Product life cycle comparison 364
14.16 2015 change in drug pricing 365
14.17 Domestic players versus MNCs by city tiers 368
14.18 Trend in R&D spend 375
14.19 Innovation among domestic players 375
14.20 R&D personnel in China 376
15.1 China’s “New Normal” 385
15.2 Growth in China’s medical device and pharmaceutical markets 386
15.3 Government policies and demographic trends 387
15.4 Infrastructure upgrades in lower-tier hospitals 388
15.5 Tiered medical system, public hospital reform, and private hospitals 389
15.6 Reform impact on hospital revenue from medical services and diagnostic procedures 390
15.7 NHFPC pilot program with 500 county hospitals, January 2015 391
15.8 Growth of private hospitals and demand for middle/high-end medical devices 392
15.9 Growth of capital equipment and reagent/consumable funding 392
15.10 Drivers of sustainable development of medical device sector 394
15.11 Medical device segments 395
15.12 Diagnostic imaging market 396
15.13 IVD market 397
15.14 Cardiovascular consumables market 397
15.15 Orthopedic market 398
15.16 Other market segments 399
15.17 Multinational medical device company challenges 400
15.18 Local medtech cost advantages relative to MNCs 401
15.19 Multinational versus local manufacturer competition 401
15.20 Hospital preference and procurement 402
15.21 Healthcare systems: China versus the United States 403
15.22 Government bureaus influencing medical device market access 405
15.23 Key concerns in regulatory environment for multinationals 406
15.24 Product registration process 407
15.25 Pricing for medical consumables 407
15.26 Pricing liberalization and decentralization in drug procurement 408
15.27 Government pricing regulation and centralized procurement 408
x List of Figures

15.28 Tendering process by product type and funding source 410
15.29 Tendering process barriers 411
15.30 Reimbursement policies favor local products 412
15.31 Needs and buying factors by customer type 413
15.32 Hospital behaviors and buying factors by tier 414
15.33 MNCs versus local firms: tailored business models 415
15.34 MNCs versus local firms: go-to-market strategy 415
15.35 MNCs versus local firms: mid-market battleground 416
15.36 Growth of mid-market Class IIA hospitals in tier 2/3 cities 416
15.37 Cardiovascular implant competitive landscape 418
15.38 Talent management 421
15.39 Lack of medtech training programs in Chinese universities 422
15.40 Capability gaps 423
15.41 M&A activity in medtech markets 425
16.1 Government and industry roles in research and development 429
16.2 New drug and biologics approvals and R&D spending 431
16.3 Global R&D spend and new molecular entities 431
16.4 Compound annual growth rate of biomedical R&D expenditures by country, adjusted for inflation, 2007–2012 432
16.5 Growth mostly in emerging markets 432
16.6 Life sciences clusters 437
16.7 Biotech sector growth relative to pharma and TCM 439
16.8 China’s innovation system in biotechnology 445
16.9 Life sciences clusters in Massachusetts 446
16.10 Scientific production versus collaboration, 2003–2009 446
Tables

1.1 China’s health improvements relative to other countries 7
1.2 Convergence between China and the United States 8
1.3 Divergences between China and the United States 9
2.1 Comparison of resources and service use between rural and urban areas 36
2.2 Central government versus subnational government spending on healthcare 41
2.3 Comparison of cooperative medical system and fee-for-service system 48
2.4 National health expenditures by source 51
3.1 Emerging and re-emerging infections 81
3.2 Top 10 reported deaths by infectious diseases, 2004–2013 82
3.3 HIV/AIDS estimates in China 83
5.1 Key announcements on major themes 139
6.1 Changes in the prevalence of chronic diseases in China, by gender, age, and place of residence, 1993–2008 151
6.2 Leading causes of deaths in China, by rank, percent of total deaths, and number of deaths per 100,000 population, 2012 154
6.3 Major risk factors in China and select OECD countries – Brazil, India, Thailand, and Vietnam – as percent of total population (male and female), 2010, 2012, and 2014 155
6.4 Number of general practitioners and nurses per 1,000 population in select OECD countries, 2014 or nearest year, and China, 2015 (GP) and 2013 (nurse) 163
7.1 Number of doctors and other health professionals in China 193
8.1 Hierarchy of China’s healthcare infrastructure 222
8.2 Regional distribution of hospitals in China, 2013 222
8.3 AEHG’s main service lines 238
8.4 Characteristics of care integration initiatives involving hospitals 241
9.1 Staff composition 258
11.1 Comparison of UEBMI, NCMS, and URBMI 297
11.2 Premium revenue for the top domestic health insurers ($ millions) 307
11.3 Top domestic private health insurers, 2012 ($ millions) 307
12.1 Insurance coverage expanded dramatically between 2000 and 2011, predominantly from NCMS 325
12.2 Counties that adopted NCMS early differed from counties that adopted NCMS later 326
12.3 Descriptive statistics 327
12.4 Regression results for correlation of NCMS adoption with health and healthcare utilization, CHNS waves 2000–2011 329
12.5 Among CHNS 2000–2011 respondents with hypertension (treated or undiagnosed), NCMS associated with some improvements in hypertension management 330
12A.1 Shandong antihypertensive study: list of antihypertensive drugs provided under the
<table>
<thead>
<tr>
<th>xii List of Tables</th>
</tr>
</thead>
<tbody>
<tr>
<td>reduced cost-sharing policy (on Essential Drugs List)</td>
</tr>
<tr>
<td>14.1 MNCs versus local players: hospital data</td>
</tr>
<tr>
<td>14.2 Top 20 therapeutic categories</td>
</tr>
<tr>
<td>14.3 MNCs with R&amp;D bases in China</td>
</tr>
<tr>
<td>16.1 Biomedical R&amp;D expenditures by the public and private sectors, adjusted for inflation, 2007–2012</td>
</tr>
<tr>
<td>16.2 Relevant policy initiatives</td>
</tr>
</tbody>
</table>
Contributors

M. Kate Bundorf is Associate Professor of Health Research and Policy at the Stanford University School of Medicine; Associate Professor, by courtesy, at the Stanford Graduate School of Business; and a Stanford Health Policy Fellow. She is also Faculty Research Fellow at the National Bureau of Economic Research. She received her MBA and MPH from the University of California at Berkeley and her PhD from the Wharton School. She was a Fulbright lecturer and visiting professor at Fudan School of Public Health in Shanghai, China, in 2009 and 2010. Her research, which focuses on health insurance markets, has been published in leading economics and health policy journals and has received funding from the US National Institutes of Health, the Agency for Health Care Research and Quality, and the Robert Wood Johnson Foundation. Specific research topics include the determinants and effects of individual and purchaser choices, the effects of regulation in insurance markets, the interaction of public and private systems of health insurance, and incentives for insurers to improve healthcare quality. Bundorf received the 13th Annual Health Care Research Award from the National Institute for Health Care Management in 2007.

Lawton Robert Burns is the James Joo-Jin Kim Professor, Professor of Health Care Management, and Professor of Management in the Wharton School at the University of Pennsylvania. He is also Director of the Wharton Center for Health Management & Economics and Co-Director of the Roy & Diana Vagelos Program in Life Sciences and Management. He received his doctorate in Sociology and his MBA in Health Administration from the University of Chicago. Dr. Burns taught previously in the Graduate School of Business at the University of Chicago and in the College of Business Administration at the University of Arizona.

Dr. Burns has analyzed physician–hospital integration and integrated delivery networks over the past 30 years. In recognition of this research, Dr. Burns recently received the 2015 Distinguished Research Scholar Award from the Academy of Management and its Health Care Administration Division. He was named the Edwin L. Crosby Memorial Fellow by the Hospital Research and Educational Trust in 1992. Dr. Burns has also published several papers on hospital systems, physician group practices, accountable care organizations (ACOs), managed care, and price transparency. He spent the last 15 years studying the healthcare supply chain. He completed a book on supply chain management in the healthcare industry, The Health Care Value Chain (Jossey-Bass, 2002), and a recent analysis of alliances between imaging equipment makers and hospital systems. These studies focus on the strategic alliances and partnerships developing between pharmaceutical firms/distributors, disposable manufacturers, medical device manufacturers, group purchasing organizations, and organized delivery systems. He has also edited The Business of Healthcare Innovation (Cambridge University Press, 2012), which analyzes the healthcare technology sectors globally: pharmaceuticals, biotechnology, medical devices, and information technology. Most recently, he has served as lead editor of the sixth edition of the major text Healthcare Management: Organization Design & Behavior (Delmar, 2011). His latest book is India’s Healthcare Industry (Cambridge University Press, 2014).

Tsung-Mei Cheng, JD, MA, is Health Policy Research Analyst at the Woodrow Wilson School of Public and International Affairs, Princeton
University, USA. Cheng’s current research focuses on cross-national comparisons of health systems in East Asia, health reforms in China and Taiwan, health technology assessment and comparative effectiveness research, healthcare quality, financing, payment reform, including evidence-based clinical guidelines and clinical pathways, and pay for performance (P4P) in East Asian health systems.

Cheng is an advisor to the National Institute for Health and Care Excellence International (NICE International) of the United Kingdom, which advises governments and agencies overseas on capacity-building for evidence base to inform national health policy as well as knowledge transfer among decision makers across national borders. She is also an advisor to the China National Health Development Research Center (CNHDRC), the official Chinese government think tank for health policy under China’s National Health and Family Planning Commission (formerly the Ministry of Health). In addition, Cheng serves as a special advisor to the Center for the Study of Major Policies (CSMP), Tsinghua University, China. Cheng is a member of the editorial board of Health Affairs, the leading US health policy journal. Cheng is also a member of the Emerging Market Symposium (EMS) Steering Committee – an Oxford University–based initiative that addresses pressing sectoral issues facing emerging market countries.

James Deng is one of the most influential healthcare industry leaders in China with over 25 years’ management experience in multinational companies. He was the first healthcare MNC China CEO with Chinese nationality when he was appointed as the president and CEO for Novartis Pharma China back in 2006. He is now Vice President, General Manager for Becton, Dickinson and Company Greater China, and also the elected Chairman of AdvaMed China Council Board for two consecutive terms. James has lectured on healthcare strategy in emerging markets in Wharton School MBA classes. James is a physician by training and also a graduate from China Europe International Business School (CEIBS) MBA class and Harvard General Management Program (GMP).

Karen Eggleston is Senior Fellow at the Freeman Spogli Institute for International Studies (FSI) at Stanford University and Director of the Stanford Asia Health Policy Program at the Walter H. Shorenstein Asia-Pacific Research Center at FSI. She is also Senior Fellow with the Center for Innovation in Global Health at the Stanford University School of Medicine and Faculty Research Fellow of the National Bureau of Economic Research. Eggleston earned her PhD in Public Policy from Harvard University in 1999. She has an MA in Economics and Asian Studies from the University of Hawaii and a BA in Asian Studies summa cum laude (valedictorian) from Dartmouth College. Eggleston studied in China for two years and was a Fulbright scholar in Korea. Her research focuses on comparative healthcare systems and health reform in Asia, especially China; government and market roles in the health sector; payment incentives; healthcare productivity; and the economics of the demographic transition. She was a consultant to the World Bank on their project on health service delivery in rural China in 2004, to China’s Ministry of Finance and the Asian Development Bank from 2010 to 2011 for an evaluation of China’s health reforms, and to the World Bank/WHO/Government of China 2015 study on China’s health service delivery system. She is a member of the Strategic Technical Advisory Committee for the Asia Pacific Observatory on Health Systems and Policies.

Vanessa Folkerts is Senior Manager for External Partnerships and Initiatives at United Family Healthcare (UFH, 和睦家医疗). UFH, the healthcare services division of Chindex International Inc., operates an expanding network of hospitals and clinics throughout mainland China, and is the only Joint Commission International–accredited healthcare system in Asia. She has been leading transactions ranging from the partial acquisition of Mongolia’s first high-end private hospital in 2014 to the development of international referral networks for medical tourism and the opening of one of China’s largest surgical training centers in 2015. She is currently managing a public–private partnership to establish China’s first US-accredited medical school. Prior to working
at UFH, Vanessa worked at Cedars-Sinai Medical Center in the Center for Neurosurgical Outcomes Research. She graduated from Princeton University with a BA in East Asian Studies.

Yanzhong Huang is Senior Fellow for Global Health at the Council on Foreign Relations and Professor and Director of the Center for Global Health Studies at Seton Hall University’s School of Diplomacy and International Relations. He is the founding editor of Global Health Governance: The Scholarly Journal for the New Health Security Paradigm. Huang has written extensively on global health governance and public health in China. He has published numerous reports, journal articles, and book chapters, including articles in *Survival, Foreign Affairs, Journal of Health Politics, Policy and Law*, as well as op-ed pieces in the *New York Times, International Herald Tribune,* and the *Lancet,* among others. He is author of *Governing Health in Contemporary China* (Routledge 2013). He is frequently consulted by major media outlets, the private sector, and governmental and nongovernmental organizations on global health issues and China. He has taught at Barnard College and Columbia University. He received his BA and MA from Fudan University and PhD from the University of Chicago.

Sam Krumholz is currently in the PhD program in Economics at the University of California, San Diego, where he is focusing on labor, environmental, and development economics. Sam has worked with the PKU China Center for Health Economic Research (PKU CCHER) on several projects relating to the economic and health effects of China’s recent healthcare reform. Prior to beginning his PhD, Sam received a master’s in Public Policy from the University of California, Los Angeles, where he worked on domestic health policy issues.

Ambar La Forgia is a doctoral student at the Department of Health Care Management and in the Wharton School, University of Pennsylvania. Ambar’s research focuses on the industrial organization of healthcare, particularly, integrated healthcare, physician networks, physician practice management, and the role of competition on hospital and physician cost and quality. To further these interests, Ambar worked as a summer associate with the Congressional Budget Office to study competition on the healthcare exchanges. She is funded by the National Science Foundation graduate research fellowship in Economics.

Prior to her doctoral studies, Ambar worked in Washington DC as a policy analyst for the Quantitative Economics and Statistics (QUEST) group of Ernst and Young. At QUEST, she worked exclusively on health industry topics, including company compliance with the Medical Device Excise Tax and nonprofit hospital compliance with uncompensated care requirements. Ambar holds a BA from Swarthmore College, where she graduated in 2011 from the honors program in Economics and Mathematics.

Gerard M. La Forgia is Lead Health Specialist at the World Bank, currently working out of Washington for the East Asia Region with primary responsibility for China. He was formerly the bank’s lead health specialist in India, Brazil, and Central America. He has published books on service delivery reform in China (2016), health insurance in India (2012), hospital performance in Brazil (2008), and health systems reforms in Central America (2005). He is also the author of a number of articles and technical reports on health systems in developing countries. Before joining the World Bank, he was a research associate at the Urban Institute and a senior health specialist at the Inter-American Development Bank. He has a ScD in Health Service Administration from the University of Pittsburgh.

Rachel Lee has been advising companies on their China strategy for over a decade. She was a partner and managing director of the Boston Consulting Group in its Shanghai office. In this capacity, she co-led the healthcare practice, published viewpoints, and spoke at industry conferences. She also briefly served as the country manager for Shire Pharmaceuticals prior to returning to the United States. Rachel holds an MBA from the Wharton School. She is a native of Nanjing, China and currently lives in San Diego, California.
Xiaofeng Liang is Deputy Director of the Chinese Center for Disease Control and Prevention (China CDC) and Director of the Tobacco Control Office of China CDC since 2011. Dr. Liang earned his medical degree at Shanxi Medical University in 1984 and then went to Gansu Province and served as a staff member of Gansu Health Bureau (1984–1992). Between 1993–1995, he obtained his Master’s in Public Health from the College of Public Health of Peking University of Medicine. After that, he was an exchange scholar at the Department of Psychiatry and Behavioral Sciences, College of Medicine, University of Miami, Florida, USA (1996–1998). He returned to China in 1998 and was the vice-director of Epidemic Prevention Station of Gansu Province (1999–2000), vice-director of the Institute of Epidemiology and Microbiology, Chinese Academy of Preventive Medicine (2000–2001), and the director of National Immunization Program, the subcenter of China CDC (2001–2011).

He was a member of the Global Strategic Advisory Group of Experts on Immunization from 2008 to 2013. He was also a member of the Chinese Committee Advisory of Immunization Practice, Chinese Association of Community Health, and Chinese Association of Prevention Medicine (Branch of Biological Products).

As the deputy director of China CDC, his research in public health led to advances in immunization, vaccination, and vaccine-preventable disease control in China. Currently, he has switched to non-communicable diseases control, nutrition, and tobacco control. He is the author of more than 30 articles in national and international journals, such as the Lancet and the New England Journal of Medicine.

Robertta Lipson is Chief Executive Officer and President of United Family Healthcare (UFH), Chindex International, Inc. Robertta co-founded Chindex in 1981 and launched the United Family Healthcare hospital brand in 1997. Under her direction, UFH has become the market leader in high-end private healthcare in China. In 2015, Lipson secured financing for the expansion of the healthcare system in a buyout that valued the company at $463 million. Lipson is an active member of the business community in Beijing. She is a governor of the American Chamber of Commerce – China, a director of the US–China Business Council, and chairwoman of the United Foundation for China’s Health, the charitable arm of Chindex. Lipson holds a BA from Brandeis University and an MBA from Columbia University.

Gordon G. Liu is a PKU Yangtze River Scholar Professor of Economics at Peking University (PKU) National School of Development, Vice-Chairman of PKU Faculty of Economics and Management, and Director of PKU China Center for Health Economic Research (PKU CCHER). His research interests include health and development economics, health reform, and pharmaceutical economics. Prior to PKU National School of Development, he was a full professor at PKU Guanghua School of Management (2006–2013); associate professor at the University of North Carolina at Chapel Hill (2000–2006); and assistant professor at the University of Southern California (1994–2000). He was the 2004–2005 President of the Chinese Economists Society and the founding chair of Asian Consortium for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Dr. Liu has served as associate editor for academic journals including Health Economics, Value in Health (The ISPOR official journal), and China Economic Quarterly. Dr. Liu sits on China’s State Council Health Reform Expert Advisory Committee and the UN SDSN Leadership Council, where he co-chairs the Health Thematic Group.

Nan Luo is Assistant Professor in Saw Swee Hock School of Public Health at the National University of Singapore (NUS). Before joining NUS, Dr. Nan Luo was a research fellow at the University of Alberta and Institute of Health Economics (Alberta, Canada). As a health services researcher, Nan Luo’s research interests are measurement of patient-reported outcomes and economic evaluation of health technologies. His main expertise is developing and validating measures of patient-reported outcomes and health-state utilities. Nan Luo has authored and co-authored more than 100 original research papers in peer-reviewed journals.
Steven M. Sammut currently holds an appointment as Senior Fellow, Health Care Management, and Lecturer, Entrepreneurship, at the Wharton School of the University of Pennsylvania, and visiting faculty at the healthcare programs at the Indian School of Business, the Strathmore Business School, and the Recanati School of Tel Aviv University. He teaches and lectures extensively on the biotechnology industry, its growth prospects, and its responsibilities for serving global needs. His research focuses on human resource capacity building in healthcare and life sciences in the emerging markets.

His 40-year career has included numerous roles as a founder and CEO of biotechnology companies, as well as a partner in biotechnology venture capital funds. He holds graduate and undergraduate degrees from Villanova University in biological sciences and ethics, holds an MBA from the Wharton School, and is a DBA candidate at the Fox School of Business at Temple University.

Claudia Süssmuth-Dyckerhoff has been Senior Partner at McKinsey’s Greater China Office and has been with McKinsey for more than 20 years – the last 11 years in China/Asia. She led McKinsey’s Asia Health Systems and Services Practice and co-led McKinsey’s Greater China Healthcare Practice. She joined McKinsey in 1995 in Switzerland. Since then, she has focused on working for healthcare companies – pharmaceutical/medical device companies, payor, provider and health systems in Europe, the United States, and, since January 2006, in Greater China and across Asia. In 1998, she joined the New Jersey Office for a 15-month period.

Most of her recent work focuses on market entry or market growth strategies, business development, assessment of potential privatization assets in the health services arena, commercial excellence, organizational redesign and capability building, post-merger integration, and operational performance improvement in hospitals.

In March 2016, she got elected as Board Member of Roche and in April 2016 she got elected as Board Member of Clariant. For McKinsey, she now acts as Senior Advisor.

Claudia holds a PhD in Business Administration from the University of St. Gallen/University of Michigan, Ann Arbor, focusing on strategy and organization, and she holds an MBA from ESADE in Barcelona. She publishes regularly on consumer and healthcare trends in China and is the proud mother of four boys and a little girl.

Florian Then is Partner at McKinsey’s Shanghai office where he is a co-leader of McKinsey’s Greater China Healthcare Practice. He joined McKinsey in 2007 and has since worked extensively with health systems, healthcare providers, and in the health insurance field. He has spent seven years in China. Florian is a physician by background, trained in Munich, Boston, and Nanjing. He completed his doctoral thesis in tumor immunology. After working in clinical medicine for some time, he moved on to pursue postdoctoral studies at Institute for Neurodegenerative Disease at Massachusetts General Hospital.

Margaret Triyana is currently Assistant Professor at the Division of Economics at Nanyang Technological University, Singapore. She holds a PhD and a BS from the University of Chicago, and was previously the Asia Health Policy Postdoctoral Fellow at the Shorenstein Asia-Pacific Research Center at Stanford University. Triyana’s main research interest lies at the intersection of development and health economics, particularly regarding how social policies affect health outcomes for the poor, early health investments, and health-seeking behavior in limited resource settings. Her recent work includes measuring the effects of a conditional cash transfer on healthcare prices and the long-run effects of a community-based midwife program.

Yan Wang (王燕) is Deputy Director of the Division of Disease Control and Prevention, Health and Family Planning Commission of Shandong Province. She earned her PhD from Shandong University in 2007 and was a visiting scholar with the Asia Health Policy Program at the Shorenstein Asia-Pacific Research Center, FSI, Stanford University, in 2009–2010.

John Whitman has been active in the field of aging and long-term care for over 30 years. For the past 29 years, he has taught at the University of Pennsylvania’s Wharton MBA Healthcare
Management Program and has twice received the coveted Excellence in Teaching Award. John is on the Board of the Philadelphia Corporation for Aging (PCA), the third largest Area Agency for Aging in the nation, and recently completed a term on the Dean’s Advisory Board of Drexel University’s School of Public Health.

John is a graduate of the Wharton MBA Healthcare Management Program and an active member in the Alumni Association, where he served as president and received the Alumni Achievement Award. He has also taught at LaSalle University, Villanova University, and the University of Pennsylvania’s School of Nursing. In addition, John has presented at over 400 national, state, and local professional organizations on a wide array of topics related to care of seniors.

Winnie Yip is Professor of Health Policy and Economics at the Blavatnik School of Government, University of Oxford, and Senior Research Fellow of Green Templeton College, Oxford, where she directs the Global Health Policy Program. She is also Adjunct Professor of International Health Policy and Economics at Harvard School of Public Health, where she was a faculty member before moving to Oxford. Winnie received her PhD in Economics from the Massachusetts Institute of Technology and BA in Economics from the University of California, Berkeley.

Winnie’s primary research interests include: (1) the design, implementation, and evaluation of health system interventions for improving affordable and equitable access and delivery of quality healthcare, especially for those most in need and (2) modeling and evaluating the effects of incentives on the behavior of providers (organization and individual) and patients. In addition, she is an expert on China’s healthcare system. Her works have been funded, among others, by the Bill and Melinda Gates Foundation, the Health Result Innovation Trust Fund (HRITF) of the World Bank, the National Science Foundation (US), the European Union Commission and the Economics and Social Science Research Council (UK).

Winnie is a member of the Institute of Medicine (US) Standing Committee to Support USAID’s Engagement in Health Systems Strengthening, the United Nations Sustainable Development Solutions Network’s Health for All Thematic Group on the post-2015 sustainable development goals and strategies, and the Lancet Global Surgery Commission to promote affordable access and delivery of effective and safe surgical care worldwide. She has served as consultant to the World Bank and the World Health Organization and has extensive executive training experience in Asia, especially China. In addition, she is Associate Editor of Health Economics, The Journal of the Economics of Ageing, and Health Systems and Reform, and an editorial board member of Health Policy, Health Economics, Policy and Law (Cambridge University Press).

Zhongyun Zhao is Director of Global Health Economics at Amgen. Before joining Amgen, Dr. Zhao worked for Merck-Medco, Eli Lilly, and Johnson & Johnson in the United States and China National Commission of Development and Reform in Beijing, China. He received his PhD in Economics from the University of Southern California. His research interests include health economics, outcomes research, market access, and health policy, primarily in therapeutic areas of oncology, neuroscience, and cardiovascular disease. Dr. Zhao has authored and co-authored more than 250 manuscript, poster, and abstract publications.

Sen Zhou is a doctoral student in Economics of Education and International Comparative Education program at the Stanford Graduate School of Education. She holds a BA in Law from Beijing International Studies University and an MA in Economics of Education from Peking University. Her interests include higher education, educational choices, health economics, and literacy development. Her dissertation is on the distribution of higher education opportunities in China.
A national healthcare system has many interconnected sectors composed of public and private organizations. These sectors, circumscribed by the governance structure and the dynamics of the marketplace, interact with each other. China, a nation with a vast landmass and 1.38 billion people, has a complex bifurcated healthcare system that affects the sectors. The financing and delivery systems are different for urban and rural residents. There is no comprehensive book that informs interested people and students about the intricate and multifaceted Chinese healthcare system. The editors of this volume, Lawton Robert Burns and Gordon G. Liu, have undertaken an ambitious endeavor in giving a comprehensive coverage of the sectors in China’s healthcare system. They have assembled a group of experts to write on these different sectors. The editors’ ambitious coverage also extends to the recent Chinese health system reforms since 2009.

In order to understand China’s current healthcare system, its various sectors with their behavior and performance, the reader must grasp the history of Chinese health policies that molded the system. The traumatic shift from central planning to a market-driven healthcare after the liberalization of the Chinese economy in 1978 caused China’s healthcare system to become convoluted with contradictory goals and incentives for healthcare providers and health-product producers such as pharmaceutical companies. The health reforms introduced since 2009 have tried to correct some of the previous haphazard policies and the resulting discordant governance and incentive structures that impacted the various sectors.

China’s health policy that governs the health system vacillates between the public sector goal of equity and the efficiency that a free market with its driving force of profit motive can bring. Equity was the hallmark of China under the Chinese Communist government prior to 1978. The economic liberalization in 1978 sharply reduced government revenues and prompted the switch to private household financing. Nevertheless, the government wanted to assure that most people had access to affordable basic healthcare by regulating health service prices, setting them below the actual costs. At the same time, the government allowed profit margins on drugs and new diagnostic and laboratory tests so that providers could earn income and profits to sustain themselves. Under this policy, the government induced its public providers (i.e., hospitals and clinics) to become for-profit public organizations to garner their income in an unregulated (other than prices) marketplace. To generate income and profits, providers resorted to vast over-treatment, over-prescribing, and over-testing. Meanwhile, the producers (i.e., pharmaceuticals and medical devices), who supplied the technological inputs to the providers operating in this distorted marketplace, responded accordingly. The production and distribution of pharmaceuticals became the key Chinese sector to drive up the cost of healthcare. In short, the development of China’s healthcare system since 1978 can best be understood by viewing it through the lens of China’s attempts to balance equity and capricious market forces.

The bifurcation of the Chinese healthcare system between urban and rural was largely due to the financial survival of providers, who mainly depended on what their patients were able and willing to pay (until the 2009 reform). With the huge income disparity between China’s rural and urban residents, partly a result of the residency (hukou) system, the providers in urban and rural
communities offer vastly different healthcare in terms of quality and sophistication. When the demand and supply of healthcare depends largely on patients’ income, the affluent and the poor also access vastly different healthcare. In sum, China has third-world as well as first-world healthcare, coexisting side by side, as the cover of this book suggests.

This book organizes the sectors in the healthcare system in three categories: the providers (physicians, hospitals, and long-term care facilities), payers (public and private insurance, drug approval, and reimbursement), and producers (pharmaceuticals, medical technology, and biotechnology). The editors and authors break new ground by bringing the producers into the picture, offering analysis and new information about the less-documented side of China’s healthcare system. The editors also address the critical sector of human resources and medical education.

In sum, China’s Healthcare System and Reform is a groundbreaking book that gives a more holistic understanding of China’s healthcare system by organizing the information into sectors. It will stimulate policy analysts to think about how to design policy to create the “best” governance and incentives for interactions among the sectors. It will stimulate the managers in each sector about how to strategize the future of their businesses in dealing with the other sectors. Lastly, this book paves the way for researchers to examine the dynamic interactions between the sectors, a desired effort in deepening our knowledge of healthcare systems globally.

William C. Hsiao, PhD

K.T. Li Research Professor of Economics
T.H. Chan School of Public Health
Harvard University
January 2016
Preface

It is a daunting task to analyze the entire healthcare system of any country. One reason is that there is no real “system” of healthcare. Rather, there are multiple firms that (a) span multiple industry sectors, such as hospitals, physicians, insurers/insurance funds, and pharmaceutical companies (b) transact with one another and (c) respond to a complex web of regulatory and reimbursement regimes (d) developed by multiple government ministries/agencies at various geographic levels. In other words, the healthcare system is a confusing mess. This is true of every country. The two editors have taught for years on the structure and functioning of their native systems (the United States and China). The lead editor has also published an analysis of India’s healthcare system that consumed 600 pages of print. Although challenging, the task is important. One cannot understand any particular segment of one’s own healthcare system without knowing (a) how it impacts, and is impacted by, developments in other adjacent segments, and (b) how it is shaped by government regulation and policy. With regard to the first assertion, the editors discovered long ago that both the quality and cost of care are inextricably tied to the behavior of physicians practicing inside and outside the walls of hospitals, as well as to the methods used by insurers to reimburse both sets of providers. With regard to the second assertion, the second editor has long been engaged in policy formation in China with an end to changing provider behavior, making healthcare services more accessible and affordable, and increasing the capacity of the delivery system to provide higher quality care and satisfy unmet demand.

Moreover, the task is particularly important for China as the country invests heavily in improving the capacity and skill levels of its delivery system, the breadth and depth of its insurance schemes, and the quality and accessibility of new medical technologies. The country is so large, both in terms of population and geographic size, that these investments will likely fuel rising public expectations and costs of care.

The opportunity to pursue this task and prepare this volume arose serendipitously from the initial meeting of the two editors in August 2009. Professor Burns traveled with a small contingent of Wharton faculty members to China to learn about the Chinese context and incorporate more global lessons into both their research and classrooms. During this trip, he spent a day with Professor Liu and his health economics research team. At the time, Gordon was on the faculty of the Guanghua School of Management, Peking University’s business school, and was already centrally involved in the ongoing state health reforms in China. The two editors exchanged perspectives on the US and Chinese healthcare systems and the impending reforms in both countries.

At the same time, the Wharton School developed a strategy of “global modular courses” (GMCs) to teach global subject matter in countries around the world. GMCs were MBA courses taken for credit by Wharton students who (along with the professor) would fly to distant sites for one to two weeks. Professor Burns taught the first such GMC on “India’s Healthcare System” at the Indian School of Business in 2010 and then again in 2011. In 2012, professors Burns and Liu collaborated on a second healthcare GMC, a joint MBA course on “The Chinese Healthcare System and Reform,” hosted at Guanghua and attended by both Wharton and Guanghua students. They repeated the course in 2013. The instructors invited Chinese executives and consultants from the healthcare industry to teach several of the class sessions. They, along with professors Liu and Burns, author many of the chapters in this volume. The editors also asked...
several leading scholars on China from around the world to contribute additional chapters that nicely round out the book’s content.

The book has thus been six years in the making. The rough outline of chapters has evolved in an iterative fashion to become this text. This evolution has occurred as China’s healthcare reforms have unfolded and the country’s healthcare issues have become more striking. The book has also evolved as the editors developed a collegial network of researchers all focused on the same issues. We are very thankful that they have joined us in this endeavor. They are all first-rate scholars who are well known in their own right. Working together and with them has been perhaps one of the most gratifying experiences the editors have ever had. We trust you will enjoy reading this as much as we enjoyed writing it.
Acknowledgments

Lawton Robert Burns

I first wish to thank Wharton’s Vice Dean for Wharton Global Initiatives, Professor Harbir Singh. Harbir not only encouraged me to travel to China in August 2009 as part of a Wharton Faculty immersion but also arranged the site visit to the Guanghua School of Management and my first meeting with Professor Gordon G. Liu. Harbir subsequently encouraged me to teach Wharton’s first GMC on “India’s Healthcare Industry” (2010) and a subsequent GMC on “China’s Healthcare Industry and Reform” (2012). When asked to do the latter, I immediately reached out to Gordon to assist me with the course and stage it at the Guanghua School of Management.

I cannot thank Gordon enough for his willingness to co-teach the class with someone he barely knew and who was a relative newcomer to both global health and the Chinese context. Gordon shared a lot of research and invaluable insight into China’s healthcare system to help me get up to speed. Based on my experience at Wharton and other business schools, it is unusual for economists like Gordon to teach and write with management professors like myself. We are trained very differently, think very differently, and conduct research very differently. After six years of dialogue and collaboration, Gordon and I have found it very easy to work together in compiling this volume.

I also thank Professor Ziv Katalan, Managing Director for Wharton Global Initiatives, who steadfastly supported and encouraged me in teaching both GMCs. Ziv actually flew to one of the sites and attended class in order to assist me. I am also grateful to Wharton’s Dean, Geoffrey Garrett, who graciously attended a “master class” on China’s healthcare system that I taught in Beijing during the summer of 2014.

In fashioning the course curriculum and lecture material, I necessarily relied on a lot of people who have studied the topic for some time. These included, first of all, Professor Liu, a distinguished scholar of China’s healthcare system. I also relied heavily on several Wharton and Guanghua teaching assistants, all of whom were Chinese and had worked in the industry, or had studied various sectors in China. They include (in alphabetical order): Di Cai, Cang Fu, Vivian Hsu, Jennifer Lee, Tianyue Ruan, Yonghui Shi, Xi Xie, Ying Zhang, and Yanan Zhu. I have also learned a considerable amount from the healthcare industry executives who came to speak to our Guanghua class or sent me background reading material (again, in alphabetical order): Chuan Chen, James Deng, James Huang, Rachel Lee, Xiaofeng Liang, Roberta Lipson, Katherine Lu, Li Ma, Jeff Towson, Jian Wang, Xiaobin Wu, and Xin Zhang. Finally, I wish to thank some of my friends in the consulting community who shared with me presentations on China’s healthcare industry: Claudia Suessmuth-Dyckerhoff and Jonathan Wang.

Every author knows the singular importance of a good editor and editorial help. Many thanks to Chris Harrison and Paula Parish at Cambridge University Press for adroitly seeing the potential of a volume like this. My administrative assistant, Tina Horowitz, did excellent work in editing this entire volume. I hired her exclusively for this task and she did not disappoint.

Finally, I want to thank my wife, Alexandra, who initially suggested to me that I ought to get more “global” in my research and consider countries like China. She has patiently endured the last nine months as Gordon and I prepared this volume.

xxiii
xxiv  Acknowledgments

Gordon G. Liu

First of all, my greatest thanks go to Professor Robert Burns for inviting me to join in this great effort to prepare this volume. It has been an honor and a wonderful opportunity to co-teach the joint Wharton–Guanghua MBA course on China’s healthcare system and reform held four years ago at PKU’s Guanghua School of Management. It was really his idea, courage, and leadership to develop such a comprehensive syllabus for the class, followed by his highly professional and patient guidance in editing the book. I have enjoyed greatly and learned so much from Robert throughout the class and the editorial work.

Second, I wish to thank our teaching assistants for the class and my research assistants for assisting me in editing some of the chapters. In particular, I want to thank Mr. Sam Krumholz for his major contribution to a chapter we have co-authored in this volume, and also for his extremely helpful assistance in my other related research. Sam is currently pursuing his PhD in Economics at UCSD. I am also very grateful to the students from both Wharton and Guanghua, who took the class in 2012 and 2013, for their contribution through active participation, discussion, and feedback. Their contribution was crucial to making this volume more comprehensive and interesting.

Finally, I want to join Robert again in thanking all the chapter contributors for their input to this volume. I trust we will find more opportunities in the future to conduct collaborative work.